TY - JOUR
T1 - Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations
T2 - Impact on the practice
AU - Fabi, Alessandra
AU - Moscetti, Luca
AU - Ciccarese, Mariangela
AU - Caramanti, Miriam
AU - Salesi, Nello
AU - Verde, Nicla La
AU - Russillo, Michelangelo
AU - Generali, Daniele
AU - Scandurra, Giuseppina
AU - Vari, Sabrina
AU - Pacetti, Umberto
AU - Cognetti, Francesco
AU - Giannarelli, Diana
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Aim: This multicenter study describes the effectiveness of eribulin in current practice. Patients & methods: In total, 78 patients with advanced metastatic breast cancer, previously treated with two or more chemotherapy lines were enrolled. Results: The median duration of response and disease stability were 7.5 (5.4-9.5) and 8.9 (6.2-11.6) months, respectively, with a clinical benefit (CB) at 6 months in 41% of patients. CB in visceral and nonvisceral metastases were 72.7 and 88.9%, respectively. Eribulin was active also in brain metastases, with 47% CB. The activity was shown in all biological subtypes. Toxicities were manageable. Conclusion: Our study confirms the effectiveness of eribulin mesylate in the treatment of patients with metastatic breast cancer and two or more lines of chemotherapy, in particular in the good disease control at the different metastatic sites.
AB - Aim: This multicenter study describes the effectiveness of eribulin in current practice. Patients & methods: In total, 78 patients with advanced metastatic breast cancer, previously treated with two or more chemotherapy lines were enrolled. Results: The median duration of response and disease stability were 7.5 (5.4-9.5) and 8.9 (6.2-11.6) months, respectively, with a clinical benefit (CB) at 6 months in 41% of patients. CB in visceral and nonvisceral metastases were 72.7 and 88.9%, respectively. Eribulin was active also in brain metastases, with 47% CB. The activity was shown in all biological subtypes. Toxicities were manageable. Conclusion: Our study confirms the effectiveness of eribulin mesylate in the treatment of patients with metastatic breast cancer and two or more lines of chemotherapy, in particular in the good disease control at the different metastatic sites.
KW - brain metastases
KW - eribulin
KW - metastatic breast cancer
KW - triple negative
UR - http://www.scopus.com/inward/record.url?scp=84923095976&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84923095976&partnerID=8YFLogxK
U2 - 10.2217/fon.14.271
DO - 10.2217/fon.14.271
M3 - Article
C2 - 25675124
AN - SCOPUS:84923095976
VL - 11
SP - 431
EP - 438
JO - Future Oncology
JF - Future Oncology
SN - 1479-6694
IS - 3
ER -